アジア太平洋の非アルコール性脂肪性肝炎(NASH)バイオマーカー市場予測:2021-2028

◆英語タイトル:ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028
◆商品コード:INK21MC013
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2021年1月25日
◆ページ数:142
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥142,500見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥171,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Inkwood社の本調査レポートは、アジア太平洋の非アルコール性脂肪性肝炎(NASH)バイオマーカー市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別分析、エンドユーザー別分析、地域別分析、競争状況などの情報をお届けいたします。
【レポートの概要】

KEY FINDINGSThe Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker market is predicted to record a CAGR of 23.00% during the forecast period, 2021-2028. The rising health awareness is among the primary drivers of market growth, along with a developing healthcare infrastructure.

MARKET INSIGHTS
The Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker market growth evaluation entails the assessment of Australia & New Zealand, Japan, China, Vietnam, India, Indonesia, South Korea, and Rest of Asia Pacific. Japan has been witnessing an increase in Non-alcoholic fatty liver disease (NAFLD) and lifestyle diseases following the growing population, for the past few years. Since NASH is highly prevalent in morbidly obese patients, interventions are being undertaken. A study by Okanoue et al. has established that around 20%-25% of diabetes mellitus patients are diagnosed with NAFLD, with the prevalence of NASH evaluated to be more than 30%-40%. The country is thus focused on raising awareness about such diseases, given their increasing prevalence.
According to the Gastroenterological Society of Australia (GESA), fatty liver is one of the common diseases in Australia. It is also one of the reasons for abnormal liver tests and ultrasound. NALFD affects almost 34% of the adult Australian population, and 13% in New Zealand. It is also the most prevalent cause of chronic liver disease. Moreover, it is expected to emerge as one of the most common liver transplant indications in the next decade. In Thailand, obesity has increased in male adults, leading to an increase in non-communicable diseases. Thus, the surging obesity cases are one of the drivers of market growth.

COMPETITIVE INSIGHTS
Some of the leading companies in the market are Siemens Healthineers, Zydus Cadila, Novo Nordisk, Viking Therapeutics, Pfizer Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING NASH AFFECTED POPULATION
3.1.2. SURGING PREVALENCE OF OBESITY AND DIABETES
3.1.3. INCREASING OCCURRENCE OF CHRONIC DISEASES
3.1.4. SURGING AWARENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE
3.2. KEY RESTRAINTS
3.2.1. SIDE-EFFECTS AND RISKS ASSOCIATED WITH NASH THERAPEUTICS
3.2.2. LACK OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. SERUM BIOMARKER
5.2. HEPATIC FIBROSIS BIOMARKER
5.3. APOPTOSIS BIOMARKER
5.4. OXIDATIVE STRESS BIOMARKER
5.5. OTHER TYPES
6. MARKET BY END-USER
6.1. PHARMA & CRO INDUSTRY
6.2. DIAGNOSTIC LAB
6.3. ACADEMIC RESEARCH KEY
6.4. HOSPITAL
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. KEY GROWTH ENABLERS
7.1.3. KEY CHALLENGES
7.1.4. KEY PLAYERS
7.1.5. COUNTRY ANALYSIS
7.1.5.1. CHINA
7.1.5.2. JAPAN
7.1.5.3. AUSTRALIA & NEW ZEALAND
7.1.5.4. INDIA
7.1.5.5. SOUTH KOREA
7.1.5.6. THAILAND
7.1.5.7. INDONESIA
7.1.5.8. VIETNAM
7.1.5.9. REST OF ASIA PACIFIC
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGER & ACQUISITIONS
8.1.2. PRODUCT LAUNCH & DEVELOPMENTS
8.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
8.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
8.2. COMPANY PROFILE
8.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
8.2.2. ASTRAZENECA
8.2.3. BRISTOL-MYERS SQUIBB COMPANY
8.2.4. GENFIT SA
8.2.5. GILEAD SCIENCES INC
8.2.6. MADRIGAL PHARMACEUTICALS
8.2.7. MERCK & CO
8.2.8. NOVARTIS AG
8.2.9. NOVO NORDISK
8.2.10. PFIZER INC
8.2.11. SIEMENS HEALTHINEERS
8.2.12. VIKING THERAPEUTICS
8.2.13. ZYDUS CADILA

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER
TABLE 2: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: LEADING PLAYERS OPERATING IN ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020
FIGURE 6: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020
FIGURE 12: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 17: CHINA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 18: JAPAN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 19: AUSTRALIA & NEW ZEALAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 20: INDIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 21: SOUTH KOREA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 22: THAILAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 23: INDONESIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 24: VIETNAM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 25: REST OF ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋の非アルコール性脂肪性肝炎(NASH)バイオマーカー市場予測:2021-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆